![Richard S. Shames](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard S. Shames
Keine laufenden Positionen mehr
Karriereverlauf von Richard S. Shames
Ehemalige bekannte Positionen von Richard S. Shames
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PROTAGONIST THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2015 | 09.05.2019 |
Aldea Pharmaceuticals, Inc.
![]() Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2013 | 01.01.2015 |
MERCK & CO., INC. | Corporate Officer/Principal | 01.01.2009 | 01.01.2013 |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Corporate Officer/Principal | 01.01.1999 | 01.01.2009 |
University of California | Corporate Officer/Principal | - | - |
Stanford University | Corporate Officer/Principal | - | - |
Ausbildung von Richard S. Shames
University of California | Doctorate Degree |
Stanford University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
PROTAGONIST THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Aldea Pharmaceuticals, Inc.
![]() Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | Health Technology |
Abbott Biotherapeutics Corp.
![]() Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
- Börse
- Insiders
- Richard S. Shames
- Erfahrung